SCI时时刷

search
+
Policy predictive model for better management of chronic obstructive pulmonary disease: economic-organisational implications in the Italian healthcare system
Istituto Superiore di Sanità (ISS), - EpiCentro – L’epidemiologia per la sanità pubblica. Broncopneu...
A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction
Bennett J, Das JM, Emmady PD. Spinal cord injuries. StatPearls Treasure Island, Florida: StatPearls ...
Survival, treatment duration and costs of patients with prostate cancer treated with triptorelin in Italy: a study of administrative databases
Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France. 2020. https:...
The economic and social burden of congenital thrombotic thrombocytopenic purpura (cTTP) in Italy
Sukumar S, Lämmle B, Cataland SR. Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, a...
Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):6...
Budget impact analysis on the Italian healthcare system of roxadustat for the treatment of anemia due to chronic kidney disease
WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity Vitamin and ...
Assessment of innovativeness, and price and reimbursement negotiation of medicines: recommendations of an expert panel
Garattini L, Cornago D, De Compadri P. Pricing and reimbursement of in-patent drugs in seven Europea...
Exploring the administrative burden faced by hematologists: a comprehensive study in Italy
Erickson SM, Rockwern B, Koltov M, McLean RM; Medical Practice and Quality Committee of the American...
Cabozantinib use in second or subsequent line of treatment in renal cell carcinoma: an analysis of Italian administrative databases
Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon, France 2020: https:/...
Early access programs for medicines: a reform proposal for the Italian National Health Service
Popoli, P., Giuliani, G., Cavaliere, A., & Jommi, C. (2024). Early access programs for medicines: a reform proposal...
How effective are prescriptive governance tools? Results from the application of AIFA notes
Agenzia Italiana del Farmaco (AIFA). Note AIFA | [Internet]. (Accessed September 2023) Online: https...
Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular Risk Evaluation)
Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women Effective CArdiovascular ...
The economic impact of 14 compassionate use programs for medicines in Italy, in the perspective of the National Health Service
Polak TB, van Rosmalen J, Uyl-de Groot CA. Expanded Access as a source of real-world data: an overvi...
Determining value in the treatment of activated PI3Kδ syndrome in Spain: a multicriteria decision analysis from the perspective of key stakeholders
Vanselow S, Wahn V, Schuetz C. Activated PI3Kδ syndrome – reviewing challenges in diagnosis and trea...
Patient-reported outcomes in epilepsy: a case study exploring their usage and impact
Food and Drug Administration. U.S. Department of Health and Human Services. Patient-Reported Outcome...
Costs and benefits in patients with NYHA class III heart failure treated with CardioMEMS in Italy
Brugts JJ, Radhoe SP, Clephas PRD, et al; MONITOR-HF investigators. Remote haemodynamic monitoring o...
Regional administrative data and their role in planning, programming and controlling at regional level
Marzona, I., Stella, P., Trifirò, G., & Corrao, G. (2024). Regional administrative data and their role in planning,...
Heart failure and economic impact: an analysis in real clinical practice in Italy
Watson RD, Gibbs CR, Lip GY. ABC of heart failure. Clinical features and complications. BMJ. 2000;32...
The socioeconomic burden of adult attention-deficit/hyperactivity disorder in Spain
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ...
The role and impact of health economics in the optimization of patient care in osteoarthritis: insights from a practical example
Vos T, Lim SS, Abbafati C, et al; GBD 2019 Diseases and Injuries Collaborators. Global burden of 369...
Regional Formularies in Italy: current state and future perspectives
Jommi C, Pippo L, Bortolami A et al. Il governo dell’assistenza farmaceutica in Italia: il ruolo di ...
Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis
Burr NE, Gracie DJ, Black CJ, Ford AC. Efficacy of biological therapies and small molecules in moder...
HTA regulation: how is Italy moving?
Authors Francesca Patarnello Vice-President Market Access ...
Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-360. https://doi.o...
Clinical and economic burden of peristomal skin complications: Activity Based Costing analysis
Robertson I, Leung E, Hughes D, et al. Prospective analysis of stoma-related complications. Colorect...
Italian healthcare resource consumption for patients on hemodialysis treated for chronic kidney disease-associated pruritus (CKD-aP)
Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and p...
The future of drugs distribution in the National Health System
Osservatorio Farmaci Cergas, Università Bocconi. Report n. 42 – Report annuale per il 2021 https://c...
A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas
Chanson P, Maiter D. The epidemiology, diagnosis and treatment of prolactinomas: the old and the new...
Orphan drugs in Italy: availability and time-to-access at regional level
European Medicines Agency. Human regulatory. Orphan designation. https://www.ema.europa.eu/en/human-...
Time to market access in Italy: duration of the P&R process for rare disease drugs
Kwon HY, Kim H, Godman B. Availability and Affordability of Drugs With a Conditional Approval by the...
阅读更多
format_indent_increase